The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer.
Abstract
The liver X> or = receptor alpha (LXRalpha) is a nuclear receptor with a key role in bile acid biosynthesis and cholesterol metabolism. The present study investigated the expression and function of LXRalpha in the normal and malignant human breast. LXRalpha mRNA transcripts were detected by RT-PCR in nine breast carcinoma cell lines. The nucleotide sequence of the cloned PCR product was identical to the corresponding human LXRalpha cDNA sequence. Expression of LXRalpha protein was confirmed by immunoblot analysis of breast cancer cell lysates. LXRalpha mRNA was expressed in 14/15 (93%) of normal human breast mammoplasty specimens and in 11/15 (73%) of primary breast carcinomas. Oxysterol and nonsteroidal LXRalpha agonists at low micromolar concentrations inhibited proliferation of breast carcinoma cell lines in culture. The importance of LXRalpha signaling in cholesterol homeostasis and the observed expression of LXRalpha in normal breast tissue suggest that this nuclear oxysterol receptor has an important physiological function in the breast. LXRalpha gene expression is regulated by dietary fatty acids implicated in breast carcinogenesis and detection of LXRalpha expression in breast cancer cell lines and breast tumors in the present study indicates that LXRalpha may also be important in breast carcinogenesis. Inhibition of breast cancer cell proliferation suggests that pharmacological LXRalpha agonists may have potential preventive and/or therapeutic antitumor activity in breast cancer.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | breast
|
유방 | dict | 16 | |
| 시술 | mammoplasty
|
유방성형술 | dict | 1 | |
| 해부 | nuclear oxysterol receptor
|
scispacy | 1 | ||
| 해부 | liver
|
scispacy | 1 | ||
| 해부 | nuclear
|
scispacy | 1 | ||
| 해부 | breast carcinoma cell lines
|
scispacy | 1 | ||
| 해부 | breast cancer cell
|
scispacy | 1 | ||
| 해부 | breast tissue
|
scispacy | 1 | ||
| 해부 | breast cancer cell lines
|
scispacy | 1 | ||
| 약물 | oxysterol
|
C4277571
Oxysterols
|
scispacy | 1 | |
| 약물 | cholesterol
|
C0008377
cholesterol
|
scispacy | 1 | |
| 약물 | nucleotide
|
C0028630
Nucleotides
|
scispacy | 1 | |
| 약물 | bile acid
|
scispacy | 1 | ||
| 약물 | micromolar
|
scispacy | 1 | ||
| 질환 | breast cancer
|
C0006142
Malignant neoplasm of breast
|
scispacy | 1 | |
| 질환 | breast carcinoma
|
C0678222
Breast Carcinoma
|
scispacy | 1 | |
| 질환 | primary breast carcinomas
|
scispacy | 1 | ||
| 질환 | breast carcinogenesis
|
scispacy | 1 | ||
| 질환 | breast tumors
|
C1458155
Mammary Neoplasms
|
scispacy | 1 | |
| 질환 | malignant human breast
|
scispacy | 1 | ||
| 질환 | breast carcinomas
|
scispacy | 1 | ||
| 질환 | antitumor
|
scispacy | 1 | ||
| 기타 | LXRalpha
→ liver X> or = receptor alpha
|
scispacy | 1 | ||
| 기타 | human breast
|
scispacy | 1 | ||
| 기타 | human LXRalpha
|
scispacy | 1 | ||
| 기타 | human breast mammoplasty specimens
|
scispacy | 1 | ||
| 기타 | Oxysterol
|
scispacy | 1 | ||
| 기타 | LXRalpha agonists
|
scispacy | 1 | ||
| 기타 | fatty acids
|
scispacy | 1 |
MeSH Terms
Breast; Breast Neoplasms; Carcinoma; Cell Transformation, Neoplastic; Cholesterol; DNA-Binding Proteins; Female; Gene Expression Profiling; Humans; Immunoblotting; Liver X Receptors; Orphan Nuclear Receptors; RNA, Messenger; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.